Siponimod Synthesis and Crystalline Forms for MS Treatment
Solution Overview
Problem
Current processes for manufacturing Siponimod, a treatment for multiple sclerosis, lack efficiency and scalability, and there is a need for improved solubility and stability forms to enhance its bioavailability and pharmaceutical compositions.
Innovation Solution
A novel process for synthesizing Siponimod involving the conversion of intermediates with hydroxylamine and suitable bases, along with the development of crystalline forms and co-crystals with organic acids like adipic and glutaric acid to enhance solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional processes are used for manufacturing Siponimod, then the synthesis can be performed with existing methods, but the process lacks efficiency and scalability
Solution Approach 1:
The patent divides the synthesis into distinct modular stages: formation of the azetidine core (Formula IV), introduction of the oxime functionality (Formula III), and final coupling with the substituted benzyl group (Formula I). Each stage can be independently optimized and scaled, with intermediates that can be isolated and characterized, enabling flexible manufacturing planning and scale-up.
Solution Approach 2:
The patent performs preliminary functional group transformations on the azetidine core before final assembly, specifically pre-installing the oxime functionality and preparing the aromatic building blocks with appropriate leaving groups. This preliminary preparation of intermediates with reactive functionalities enables more efficient final coupling steps and improves overall process scalability.
2Reliability
If Siponimod is administered in its current form, then the drug can be delivered, but the solubility and bioavailability are limited
Solution Approach 1:
The patent creates crystalline forms and salts of Siponimod with different physical and chemical parameters. By varying the counterion (e.g., fumarate, maleate, tartrate) or establishing specific crystal packing arrangements, the patent modifies solubility parameters while maintaining the active pharmaceutical ingredient's identity, thereby improving bioavailability without changing the molecular structure of Siponimod itself.
3Ease of manufacture
If the synthesis process is simplified, then the manufacturing becomes more economical, but the purity and quality control may be compromised
Solution Approach 1:
The patent extracts and isolates key intermediates (Formula IV and Formula III) as discrete entities with defined structures and purification protocols. By separating the synthesis into stages with isolatable intermediates, the process achieves both economic simplicity (each step can be optimized independently) and high purity (each intermediate can be thoroughly purified before proceeding to the next stage).
Solution Approach 2:
The patent employs well-defined intermediate compounds as mediators between the simple azetidine core and the final complex Siponimod structure. These intermediates serve as quality control checkpoints, allowing purification and characterization at each stage, thereby ensuring high final product purity while maintaining an economical stepwise synthesis approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new process results in high-purity Siponimod with improved solubility and stability, facilitating more effective pharmaceutical compositions for treating multiple sclerosis.
Implementation Method 1
reacting compound of Formula IV with hydroxyl amine to provide compound of Formula III
Implementation Method 2
condensing compound of Formula III with compound of Formula II in the presence of a suitable base to provide Siponimod of Formula I
Implementation Method 3
development of crystalline forms and co-crystals with organic acids like adipic and glutaric acid to enhance solubility and stability
Data Source
AI summary
The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical compositions comprising the salts and solid forms and to use of said compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.